Loading…

Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99

Ewing sarcoma (ES) is an aggressive bone and soft tissue malignancy that predominantly affects children and adolescents. CD99 is a cell surface protein that is highly expressed on ES cells and is required to maintain their malignancy. We screened small molecule libraries for binding to extracellular...

Full description

Saved in:
Bibliographic Details
Published in:Oncogene 2018-04, Vol.37 (16), p.2181-2196
Main Authors: Çelik, Haydar, Sciandra, Marika, Flashner, Bess, Gelmez, Elif, Kayraklıoğlu, Neslihan, Allegakoen, David V., Petro, Jeff R., Conn, Erin J., Hour, Sarah, Han, Jenny, Oktay, Lalehan, Tiwari, Purushottam B., Hayran, Mutlu, Harris, Brent T., Manara, Maria Cristina, Toretsky, Jeffrey A., Scotlandi, Katia, Üren, Aykut
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ewing sarcoma (ES) is an aggressive bone and soft tissue malignancy that predominantly affects children and adolescents. CD99 is a cell surface protein that is highly expressed on ES cells and is required to maintain their malignancy. We screened small molecule libraries for binding to extracellular domain of recombinant CD99 and subsequent inhibition of ES cell growth. We identified two structurally similar FDA-approved compounds, clofarabine and cladribine that selectively inhibited the growth of ES cells in a panel of 14 ES vs. 28 non-ES cell lines. Both drugs inhibited CD99 dimerization and its interaction with downstream signaling components. A membrane-impermeable analog of clofarabine showed similar cytotoxicity in culture, suggesting that it can function through inhibiting CD99 independent of DNA metabolism. Both drugs drastically inhibited anchorage-independent growth of ES cells, but clofarabine was more effective in inhibiting growth of three different ES xenografts. Our findings provide a novel molecular mechanism for clofarabine that involves direct binding to a cell surface receptor CD99 and inhibiting its biological activities.
ISSN:0950-9232
1476-5594
DOI:10.1038/s41388-017-0080-4